S Munir Alam

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7631882/publications.pdf

Version: 2024-02-01

108 papers	12,216 citations	31976 53 h-index	28297 105 g-index
114 all docs	114 docs citations	114 times ranked	9865 citing authors

#	Article	IF	Citations
1	Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial. New England Journal of Medicine, 2012, 366, 1275-1286.	27.0	1,699
2	Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature, 2013, 496, 469-476.	27.8	961
3	Programming the magnitude and persistence of antibody responses with innate immunity. Nature, 2011, 470, 543-547.	27.8	847
4	Cardiolipin Polyspecific Autoreactivity in Two Broadly Neutralizing HIV-1 Antibodies. Science, 2005, 308, 1906-1908.	12.6	704
5	Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors. Journal of Virology, 2011, 85, 9998-10009.	3.4	393
6	Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2. Immunity, 2013, 38, 176-186.	14.3	374
7	Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody. Cell, 2016, 165, 449-463.	28.9	305
8	Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies. Cell, 2014, 158, 481-491.	28.9	266
9	The Role of Antibody Polyspecificity and Lipid Reactivity in Binding of Broadly Neutralizing Anti-HIV-1 Envelope Human Monoclonal Antibodies 2F5 and 4E10 to Glycoprotein 41 Membrane Proximal Envelope Epitopes. Journal of Immunology, 2007, 178, 4424-4435.	0.8	230
10	InÂvitro and inÂvivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. Cell, 2021, 184, 4203-4219.e32.	28.9	228
11	Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 20234-20239.	7.1	225
12	Staged induction of HIV-1 glycanâ€“dependent broadly neutralizing antibodies. Science Translational Medicine, 2017, 9, .	12.4	212
13	Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. Nature, 2021, 594, 553-559.	27.8	199
14	Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. Journal of Experimental Medicine, 2011, 208, 2237-2249.	8.5	198
15	Diversion of HIV-1 vaccineâ€“induced immunity by gp41-microbiota cross-reactive antibodies. Science, 2015, 349, aab1253.	12.6	191
16	Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 181-186.	7.1	172
17	Envelope residue 375 substitutions in simianâ€“human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E3413-22.	7.1	170
18	HIV-1 Vaccine-Induced C1 and V2 Env-Specific Antibodies Synergize for Increased Antiviral Activities. Journal of Virology, 2014, 88, 7715-7726.	3.4	169

#	Article	IF	Citations
19	Antibodyâ€virus coâ€evolution in <scp>HIV</scp> infection: paths for <scp>HIV</scp> vaccine development. Immunological Reviews, 2017, 275, 145-160.	6.0	160
20	Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. PLoS Pathogens, 2015, 11, e1005042.	4.7	145
21	Antibody polyspecificity and neutralization of HIV-1: A hypothesis. Human Antibodies, 2006, 14, 59-67.	1.5	142
22	Immunoglobulin Gene Insertions and Deletions in the Affinity Maturation of HIV-1 Broadly Reactive Neutralizing Antibodies. Cell Host and Microbe, 2014, 16, 304-313.	11.0	137
23	Isolation of a Human Anti-HIV gp41 Membrane Proximal Region Neutralizing Antibody by Antigen-Specific Single B Cell Sorting. PLoS ONE, 2011, 6, e23532.	2.5	137
24	Glycosylation Site-Specific Analysis of HIV Envelope Proteins (JR-FL and CON-S) Reveals Major Differences in Glycosylation Site Occupancy, Glycoform Profiles, and Antigenic EpitopesÊ¼ Accessibility. Journal of Proteome Research, 2008, 7, 1660-1674.	3.7	133
25	Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses. PLoS Pathogens, 2016, 12, e1005817.	4.7	119
26	Potent and broad HIV-neutralizing antibodies in memory B cells and plasma. Science Immunology, 2017, 2, .	11.9	119
27	Targeted selection of HIV-specific antibody mutations by engineering B cell maturation. Science, 2019, 366, .	12.6	118
28	HIV-1 Envelope gp41 Antibodies Can Originate from Terminal Ileum B Cells that Share Cross-Reactivity with Commensal Bacteria. Cell Host and Microbe, 2014, 16, 215-226.	11.0	105
29	Reconstructing a B-Cell Clonal Lineage. II. Mutation, Selection, and Affinity Maturation. Frontiers in Immunology, 2014, 5, 170.	4.8	104
30	Functional Relevance of Improbable Antibody Mutations for HIV Broadly Neutralizing Antibody Development. Cell Host and Microbe, 2018, 23, 759-765.e6.	11.0	98
31	Rescue of HIV-1 Broad Neutralizing Antibody-Expressing B Cells in 2F5 VH Ã— VL Knockin Mice Reveals Multiple Tolerance Controls. Journal of Immunology, 2011, 187, 3785-3797.	0.8	97
32	Antigenicity and Immunogenicity of RV144 Vaccine AIDSVAX Clade E Envelope Immunogen Is Enhanced by a gp120 N-Terminal Deletion. Journal of Virology, 2013, 87, 1554-1568.	3.4	97
33	Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models. Cell Reports, 2017, 21, 3681-3690.	6.4	97
34	A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice. Science Translational Medicine, 2022, 14, eabj7125.	12.4	93
35	T-cell receptor binding kinetics in T-cell development and activation. Expert Reviews in Molecular Medicine, 2001, 3, 1-17.	3.9	90
36	Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs. Blood Advances, 2017, 1, 2329-2342.	5.2	90

#	Article	IF	Citations
37	3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelopeâ€“specific plasma cells and humoral immunity in nonhuman primates. Science Immunology, 2020, 5, .	11.9	90
38	Glycosylation Site-Specific Analysis of Clade C HIV-1 Envelope Proteins. Journal of Proteome Research, 2009, 8, 4231-4242.	3.7	87
39	Initiation of immune toleranceâ€“controlled HIV gp41 neutralizing B cell lineages. Science Translational Medicine, 2016, 8, 336ra62.	12.4	86
40	Antigenicity and Immunogenicity of Transmitted/Founder, Consensus, and Chronic Envelope Glycoproteins of Human Immunodeficiency Virus Type 1. Journal of Virology, 2013, 87, 4185-4201.	3.4	83
41	Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. Science Translational Medicine, 2017, 9, .	12.4	81
42	Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual. Immunity, 2019, 50, 677-691.e13.	14.3	77
43	Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations. Nature Communications, 2017, 8, 1732.	12.8	76
44	Induction of Antibodies in Rhesus Macaques That Recognize a Fusion-Intermediate Conformation of HIV-1 gp41. PLoS ONE, 2011, 6, e27824.	2.5	75
45	Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 18214-18219.	7.1	73
46	Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers. Journal of Virology, 2017, 91, .	3.4	73
47	Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates. Cell Reports, 2017, 18, 2175-2188.	6.4	69
48	Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. Cell Host and Microbe, 2015, 18, 354-362.	11.0	66
49	Antibody Light-Chain-Restricted Recognition of the Site of Immune Pressure in the RV144 HIV-1 Vaccine Trial Is Phylogenetically Conserved. Immunity, 2014, 41, 909-918.	14.3	65
50	Conformationally selective RNA aptamers allosterically modulate the Î²2-adrenoceptor. Nature Chemical Biology, 2016, 12, 709-716.	8.0	65
51	Cold sensitivity of the SARS-CoV-2 spike ectodomain. Nature Structural and Molecular Biology, 2021, 28, 128-131.	8.2	65
52	Progress in HIV-1 vaccine development. Journal of Allergy and Clinical Immunology, 2014, 134, 3-10.	2.9	62
53	Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design. Journal of Virology, 2016, 90, 5899-5914.	3.4	62
54	Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier. Immunity, 2018, 49, 1162-1174.e8.	14.3	61

#	Article	IF	Citations
55	Chemical Synthesis of Highly Congested gp120 V1V2 N-Glycopeptide Antigens for Potential HIV-1-Directed Vaccines. Journal of the American Chemical Society, 2013, 135, 13113-13120.	13.7	60
56	Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies. Cell, 2021, 184, 2955-2972.e25.	28.9	57
57	Differential Reactivity of Germ Line Allelic Variants of a Broadly Neutralizing HIV-1 Antibody to a gp41 Fusion Intermediate Conformation. Journal of Virology, 2011, 85, 11725-11731.	3.4	56
58	Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies. PLoS Pathogens, 2019, 15, e1008026.	4.7	56
59	HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees. Journal of Virology, 2018, 92, .	3.4	46
60	Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site. Cell Reports, 2016, 14, 43-54.	6.4	45
61	HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis. Journal of Virology, 2018, 92, .	3.4	45
62	Vi-specific serological correlates of protection for typhoid fever. Journal of Experimental Medicine, 2021, 218, .	8.5	45
63	Developmental Pathway of the MPER-Directed HIV-1-Neutralizing Antibody 10E8. PLoS ONE, 2016, 11, e0157409.	2.5	44
64	A Therapeutic Antibody for Cancer, Derived from Single Human B Cells. Cell Reports, 2016, 15, 1505-1513.	6.4	43
65	An Inducible HIV Type 1 gp41 HR-2 Peptide-Binding Site on HIV Type 1 Envelope gp120. AIDS Research and Human Retroviruses, 2004, 20, 836-845.	1.1	42
66	Disruption of the HIV-1 Envelope allosteric network blocks CD4-induced rearrangements. Nature Communications, 2020, 11, 520.	12.8	42
67	Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost. Journal of Virology, 2015, 89, 6462-6480.	3.4	40
68	IgA and IgG1 Specific to Vi Polysaccharide of Salmonella Typhi Correlate With Protection Status in a Typhoid Fever Controlled Human Infection Model. Frontiers in Immunology, 2019, 10, 2582.	4.8	40
69	Adjuvant-Dependent Enhancement of HIV Env-Specific Antibody Responses in Infant Rhesus Macaques. Journal of Virology, 2018, 92, .	3.4	39
70	IGHV1-69 B Cell Chronic Lymphocytic Leukemia Antibodies Cross-React with HIV-1 and Hepatitis C Virus Antigens as Well as Intestinal Commensal Bacteria. PLoS ONE, 2014, 9, e90725.	2.5	37
71	Surface plasmon resonance measurements of plasma antibody avidity during primary and secondary responses to anthrax protective antigen. Journal of Immunological Methods, 2014, 404, 1-12.	1.4	35
72	Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations. Nature Communications, 2019, 10, 2898.	12.8	35

#	Article	IF	Citations
73	Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity. EBioMedicine, 2016, 12, 196-207.	6.1	34
74	Selection of immunoglobulin elbow region mutations impacts interdomain conformational flexibility in HIV-1 broadly neutralizing antibodies. Nature Communications, 2019, 10, 654.	12.8	34
75	Qualified Biolayer Interferometry Avidity Measurements Distinguish the Heterogeneity of Antibody Interactions with Plasmodium falciparum Circumsporozoite Protein Antigens. Journal of Immunology, 2018, 201, 1315-1326.	0.8	30
76	Impact of Poxvirus Vector Priming, Protein Coadministration, and Vaccine Intervals on HIV gp120 Vaccine-Elicited Antibody Magnitude and Function in Infant Macaques. Vaccine Journal, 2017, 24, .	3.1	28
77	Longitudinal Antigenic Sequences and Sites from Intra-Host Evolution (LASSIE) Identifies Immune-Selected HIV Variants. Viruses, 2015, 7, 5443-5475.	3.3	26
78	IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells. Communications Biology, 2018, 1, 134.	4.4	26
79	HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine. Journal of Virology, 2017, 91, .	3.4	23
80	mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice. Cell Reports, 2022, 38, 110514.	6.4	23
81	HIV-1 gp140 epitope recognition is influenced by immunoglobulin DH gene segment sequence. Immunogenetics, 2016, 68, 145-155.	2.4	18
82	HIV-1 Consensus Envelope-Induced Broadly Binding Antibodies. AIDS Research and Human Retroviruses, 2017, 33, 859-868.	1.1	18
83	Determinants of Tenascin-C and HIV-1 envelope binding and neutralization. Mucosal Immunology, 2019, 12, 1004-1012.	6.0	18
84	Coadministration of CH31 Broadly Neutralizing Antibody Does Not Affect Development of Vaccine-Induced Anti-HIV-1 Envelope Antibody Responses in Infant Rhesus Macaques. Journal of Virology, 2019, 93, .	3.4	18
85	Vaccine-Induced HIV-1 Envelope gp120 Constant Region 1-Specific Antibodies Expose a CD4-Inducible Epitope and Block the Interaction of HIV-1 gp140 with Galactosylceramide. Journal of Virology, 2014, 88, 9406-9417.	3.4	16
86	Mouse and human antibodies bind HLA-E-leader peptide complexes and enhance NK cell cytotoxicity. Communications Biology, 2022, 5, 271.	4.4	14
87	Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee. EBioMedicine, 2015, 2, 713-722.	6.1	13
88	Novel Monoclonal Antibodies for Studies of Human and Rhesus Macaque Secretory Component and Human J-Chain. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2016, 35, 217-226.	1.6	9
89	TCR Affinity Associated with Functional Differences between Dominant and Subdominant SIV Epitope-Specific CD8+ T Cells in Mamu-A*01+ Rhesus Monkeys. PLoS Pathogens, 2014, 10, e1004069.	4.7	8
90	Comprehensive Data Integration Approach to Assess Immune Responses and Correlates of RTS,S/AS01-Mediated Protection From Malaria Infection in Controlled Human Malaria Infection Trials. Frontiers in Big Data, 2021, 4, 672460.	2.9	8

#	Article	IF	Citations
91	Magnitude, Specificity, and Avidity of Sporozoite-Specific Antibodies Associate With Protection Status and Distinguish Among RTS,S/AS01 Dose Regimens. Open Forum Infectious Diseases, 2021, 8, .	0.9	8
92	Immunodominance of Antibody Recognition of the HIV Envelope V2 Region in Ig-Humanized Mice. Journal of Immunology, 2017, 198, 1047-1055.	0.8	7
93	Rapid Boosting of HIV-1 Neutralizing Antibody Responses in Humans Following a Prolonged Immunologic Rest Period. Journal of Infectious Diseases, 2019, 219, 1755-1765.	4.0	7
94	Salmonella Typhi Vi capsule prime-boost vaccination induces convergent and functional antibody responses. Science Immunology, 2021, 6, eabj1181.	11.9	7
95	HIV-1 Envelope Mimicry of Host Enzyme Kynureninase Does Not Disrupt Tryptophan Metabolism. Journal of Immunology, 2016, 197, 4663-4673.	0.8	6
96	HIV Env-Specific IgG Antibodies Induced by Vaccination of Neonatal Rhesus Macaques Persist and Can Be Augmented by a Late Booster Immunization in Infancy. MSphere, 2020, 5, .	2.9	6
97	B cells expressing IgM B cell receptors of HIV-1 neutralizing antibodies discriminate antigen affinities by sensing binding association rates. Cell Reports, 2022, 39, 111021.	6.4	6
98	T Cell Receptor Binding Kinetics and Special Role of VÎ± in T Cell Development and Activation. Immunologic Research, 2000, 21, 225-232.	2.9	5
99	Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques. Journal of Virology, 2017, 91, .	3.4	5
100	Cooperation between somatic mutation and germline-encoded residues enables antibody recognition of HIV-1 envelope glycans. PLoS Pathogens, 2019, 15, e1008165.	4.7	5
101	Antigenicity and Immunogenicity of HIV-1 Envelope Trimers Complexed to a Small-Molecule Viral Entry Inhibitor. Journal of Virology, 2020, 94, .	3.4	5
102	HIV-1 antibodies and vaccine antigen selectively interact with lipid domains. Biochimica Et Biophysica Acta - Biomembranes, 2014, 1838, 2662-2669.	2.6	4
103	Estimating the Probability of Polyreactive Antibodies 4E10 and 2F5 Disabling a gp41 Trimer after T Cell-HIV Adhesion. PLoS Computational Biology, 2014, 10, e1003431.	3.2	3
104	Vaccine-Induced, High-Magnitude HIV Env-Specific Antibodies with Fc-Mediated Effector Functions Are Insufficient to Protect Infant Rhesus Macaques against Oral SHIV Infection. MSphere, 2022, 7, e0083921.	2.9	2
105	Binding Kinetics of Superantigen with TCR and MHC Class II. , 2003, 214, 065-085.		1
106	Induction of Antibodies with Long Variable Heavy Third Complementarity Determining Regions by Repetitive Boosting with AIDSVAXÂ® B/E in RV144 Vaccinees. AIDS Research and Human Retroviruses, 2014, 30, A36-A36.	1.1	1
107	Different adjuvanted pediatric HIV envelope vaccines induced distinct plasma antibody responses despite similar B cell receptor repertoires in infant rhesus macaques. PLoS ONE, 2021, 16, e0256885.	2.5	1
108	Longitudinal Antibody Development in SHIVAD8 Infected Non-Human Primate. AIDS Research and Human Retroviruses, 2014, 30, A121-A121.	1.1	0